Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aytu Biopharma (AYTU) Raw Materials (2019 - 2026)

Aytu Biopharma has reported Raw Materials over the past 7 years, most recently at $1.2 million for Q4 2025.

  • Quarterly Raw Materials rose 144.94% to $1.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.2 million through Dec 2025, up 144.94% year-over-year, with the annual reading at $1.1 million for FY2025, 319.17% up from the prior year.
  • Raw Materials was $1.2 million for Q4 2025 at Aytu Biopharma, down from $1.4 million in the prior quarter.
  • Over five years, Raw Materials peaked at $2.6 million in Q3 2021 and troughed at $266000.0 in Q2 2024.
  • The 5-year median for Raw Materials is $1.8 million (2022), against an average of $1.6 million.
  • Year-over-year, Raw Materials skyrocketed 471.54% in 2021 and then crashed 79.55% in 2024.
  • A 5-year view of Raw Materials shows it stood at $2.4 million in 2021, then fell by 26.41% to $1.8 million in 2022, then fell by 7.39% to $1.7 million in 2023, then tumbled by 70.13% to $494000.0 in 2024, then surged by 144.94% to $1.2 million in 2025.
  • Per Business Quant, the three most recent readings for AYTU's Raw Materials are $1.2 million (Q4 2025), $1.4 million (Q3 2025), and $1.1 million (Q2 2025).